AbbVie to acquire Gilgamesh's new investigational drug bretisilocin for MDD.

On August 26th, AbbVie announced that it has reached a definitive agreement with Gilgamesh Pharmaceuticals to acquire their investigational compound bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, for the treatment of moderate to severe depression.